Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis

Guan, Yupeng; Xiong, Haiyun; Feng, Yupeng; Liao, Guolong; Tong, Tongyu; Pang, Jun

doi:10.1038/s41391-020-0209-3

Cited by 44 publications

(33 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have shown that NLR could be valuable as a prognostic indicator of solid tumors, such as breast cancer [29], melanoma [30], prostate cancer [28]. The present study aimed to investigate the role of pretreatment NLR as a prognostic biomarker in bone sarcoma.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Potential value of pretreatment neutrophil-to-lymphocyte ratio in patients with bone sarcomas

Hu¹,

Huang²,

Yang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Increasing evidence indicates the important value of the neutrophil-to-lymphocyte ratio (NLR) in various cancers. In this meta-analysis, we will explore the potential role of pretreatment NLR in patients with bone sarcomas. Methods A systematic literature search of the PubMed, Embase and Web of Science databases for relevant articles was performed with the deadline of December 29, 2019. The hazard ratio (HR) and its 95% confidence interval (CI) were calculated to evaluate the association between NLR and overall survival (OS) in patients with bone sarcomas. Results A total of 1131 patients in 6 studies were included in this meta-analysis. The pooled HR of 2.26 (95%CI: 1.83-2.69, p<0.001) indicated that an elevated NLR had an unfavourable eﬀect on OS. Subgroup analyses showed that elevated NLR was related to poor OS in patients with bone sarcomas, regardless of the type of cancer, ethnicity, sample size (≥200 or <200), the cut-off value for NLR (≥3 or <3), follow-up time (≥30 or <30) and paper quality (NOS scores ≥8 or <8). Additionally, the results of diagnosis analysis suggested that NLR had a relatively high diagnostic accuracy for bone sarcoma patients. Conclusion The results of this meta-analysis suggest that an elevated NLR is associated with poor survival of patients with bone sarcomas. Moreover, NLR had a relatively high diagnostic accuracy for bone sarcoma patients. All these findings suggest NLR might be a promising biomarker in the management of bone sarcomas.

show abstract

Section: Discussionmentioning

confidence: 98%

“…In general, impaired T-lymphocytemediated antitumor response might be related with lymphocyte depletion. Accordingly, the relative ratio of neutrophils and lymphocytes seems to reflect the systemic inflammatory response to cancer progression [28].…”

Section: Discussionmentioning

confidence: 99%

Potential value of pretreatment neutrophil-to-lymphocyte ratio in patients with bone sarcomas

Hu¹,

Huang²,

Yang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Recent studies have found NLR to be related to inferior prognosis in various solid tumors. 5,11,12,16,28 A higher NLR value often indicates a higher neutrophil or lower lymphocyte count. Neutrophils can secrete essential factors, including IL-8, VEGF, and elastase for tumor growth and metastases.…”

Section: Dovepressmentioning

confidence: 99%

“…9,10 Previous studies have presented that NLR could serve as a systemic inflammatory response index to provide important information regarding inflammation and immune state. NLR has been identified as a prognostic biomarker in several cancer types, including urinary tract epithelial tumors, prostate cancer, and non-small cell lung cancer (NSCLC), [11][12][13][14] although the relationship between NLR and long-term outcomes in SCLC remains to be completely understood. Thus, this study was designed to further explore the effects of NLR on the prognosis and identify other factors that modify this association in patients with SCLC.…”

Section: Introductionmentioning

confidence: 99%

<p>A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen</p>

Liu

Zhou

Tan

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose: Neutrophil-to-lymphocyte ratio (NLR) has been suggested as an independent risk factor for progression-free survival (PFS) and overall survival (OS) in small cell lung cancer (SCLC). However, it is still unknown whether there is a linear relationship between the NLR and the risk of death in SCLC. The objective of this study is to provide further results. Patients and Methods: A retrospective cohort study was performed among a total of 251 participants with SCLC. Smooth curve fitting and piecewise Cox regression model were used to determine the linear relationship between NLR and mortality risk. A multivariable Cox regression model was used to estimate the effects of NLR on OS. Interaction and stratified analyses were conducted according to covariates. Results: The analysis indicated no significant nonlinear relationship or threshold effect between NLR and hazard of death. Multivariate analysis revealed that every unit increase in NLR was associated with a 10% increase in mortality risk. High NLR (>3.5) at baseline was associated with poor OS (hazard ratio [HR]=1.97, P=0.009). The difference in median OS duration between the high and low NLR groups was statistically significant (9.1 months vs 14.6 months, P=0.0067). Furthermore, interaction analysis identified the chemotherapy regimen to play an interactive role in the association between NLR and hazard of death. Conclusion: NLR was identified as an independent risk factor for OS in SCLC and the linear correlation was observed between them. Administration of etoposide plus cisplatin (EP) regimen in patients with low NLR resulted in better long-term outcome than that of etoposide plus carboplatin (EC) regimen, while administration of the EC regimen conferred longer OS than that of the EP regimen in patients with high NLR.

show abstract

“…The platelet‐to‐lymphocyte ratio (PLR) is calculated as the ratio of platelets divided by lymphocyte counts. The PLR is a useful prognostic indicator in various cancers, including endometrial cancer, 8 lung cancer, 9 prostate cancer, 10 and nasopharyngeal carcinoma 11 . Recent studies have been conducted to investigate the potential prognostic role of the PLR in patients with melanoma; however, the conclusions were inconsistent 12–14 .…”

Section: Introductionmentioning

confidence: 99%

Prognostic and clinicopathological significance of the platelet‐to‐lymphocyte ratio in melanoma: A meta‐analysis involving 2099 patients

Han

Feng

Liu

2020

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

To investigate the prognostic role of the platelet‐to‐lymphocyte ratio (PLR) in melanoma through a meta‐analytical method. The literature was searched using the PubMed, Embase, Web of Science, Cochrane Library, and Scopus electronic platforms. Hazard ratios (HRs) for overall survival (OS) and progression‐free survival (PFS) and their corresponding 95% confidence intervals (CIs) were calculated. Begg's test and Egger's test were used to assess potential publication bias. A total of eight retrospective cohort studies involving 2099 patients were included in the meta‐analysis. No significant association between the PLR and OS was found (HR = 1.39; 95% CI = 0.97‐1.99; P = .075). There was also a nonsignificant correlation between the PLR and PFS (HR = 1.49; 95% CI = 0.98‐2.27; P = .065). In addition, there was no significant association between the PLR and sex (odds ratio [OR] = 1.14; 95% CI = 0.23‐5.66; P = .869) or age (OR = 0.81; 95% CI = 0.41‐1.59; P = .539). No significant publication bias was found in this meta‐analysis. The pooled analysis suggests that the PLR may not be a significant prognostic marker in patients with melanoma.

show abstract

Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis

Cited by 44 publications

References 43 publications

Potential value of pretreatment neutrophil-to-lymphocyte ratio in patients with bone sarcomas

Potential value of pretreatment neutrophil-to-lymphocyte ratio in patients with bone sarcomas

<p>A Retrospective Cohort Study on Pretreated Neutrophil-to-Lymphocyte Ratio and Prognosis of Small Cell Lung Cancer: Evidence of Effect Modification by Chemotherapy Regimen</p>

Prognostic and clinicopathological significance of the platelet‐to‐lymphocyte ratio in melanoma: A meta‐analysis involving 2099 patients

Contact Info

Product

Resources

About